EIPA
Based on 108 publication(s) in Google Scholar
EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.42%
- No. CAS: 1154-25-2
- Fòrmula: C11H18ClN7O
- Peso molecular:299.76
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) EIPA
More- Signal Transduct Target Ther. 2025 Oct 21;10(1):349. [Abstract]
- Cancer Cell. 2025 Jul 15:S1535-6108(25)00271-5. [Abstract]
- Mol Cancer. 2026 Feb 10;25(1):73. [Abstract]
- Nat Nanotechnol. 2025 Feb;20(2):296-302. [Abstract]
- Cell Metab. 2022 Dec 6;34(12):2018-2035.e8. [Abstract]
- Adv Mater. 2025 Mar;37(9):e2415030. [Abstract]
- Bioact Mater. 2026 Apr 3:62:846-861. [Abstract]
- Cancer Res. 2025 Oct 9. [Abstract]
- Cancer Res. 2025 Apr 17. [Abstract]
- Bone Res. 2025 Oct 20;13(1):88. [Abstract]
- Adv Funct Mater. 2021 Apr 1.
- Autophagy. 2023 Mar;19(3):839-857. [Abstract]
- Nat Commun. 2025 Sep 26;16(1):8522. [Abstract]
- Nat Commun. 2025 Feb 4;16(1):1327. [Abstract]
- Nat Commun. 2024 Jan 2;15(1):162. [Abstract]
- ACS Nano. 2026 Jun 30;20(25):18533-18544. [Abstract]
- ACS Nano. 2025 Aug 19;19(32):29341-29359. [Abstract]
- ACS Nano. 2024 Sep 11. [Abstract]
- ACS Nano. 2020 Nov 24;14(11):14698-14714. [Abstract]
- Matter. 2023 Aug 31.
- J Nanobiotechnology. 2022 Jul 20;20(1):340. [Abstract]
- J Nanobiotechnology. 2022 Jun 10;20(1):268. [Abstract]
- Theranostics. 2022 Jan 1;12(3):1061-1073. [Abstract]
- Interdiscip Med. 2026 May 18.
- Adv Sci (Weinh). 2026 Mar 4:e22936. [Abstract]
- Adv Sci (Weinh). 2025 Sep 3:e02788. [Abstract]
- Adv Sci (Weinh). 2025 Jun;12(21):e2415684. [Abstract]
- Adv Sci (Weinh). 2025 Jan;12(1):e2412014. [Abstract]
- Sci Adv. 2020 Aug 12;6(33):eaaz1774. [Abstract]
- Biomaterials. 2026 Aug:331:124113. [Abstract]
- Biomaterials. 2022 Feb:281:121373. [Abstract]
- Carbohydr Polym. 2025 Nov 15;368(Pt 1):124067. [Abstract]
- Chem Eng J. 2024 Sep 1.
- J Control Release. 2026 Mar 10:391:114591. [Abstract]
- J Control Release. 2026 May 10:393:114784. [Abstract]
- J Control Release. 2026 Feb 10:390:114551. [Abstract]
- J Control Release. 2025 Nov 10:387:114176. [Abstract]
- J Control Release. 2025 Sep 10:385:113939. [Abstract]
- J Control Release. 2024 Jun:370:140-151. [Abstract]
- J Control Release. 2023 Mar:355:675-684. [Abstract]
- J Control Release. 2022 Nov:351:703-712. [Abstract]
- Cell Death Dis. 2026 Jun 16. [Abstract]
- Cell Death Dis. 2026 Apr 9;17(1):485. [Abstract]
- Cell Death Dis. 2025 Apr 5;16(1):253. [Abstract]
- J Exp Med. 2023 Mar 6;220(3):e20221316. [Abstract]
- J Neuroinflammation. 2024 May 10;21(1):125. [Abstract]
- Mater Today Bio. 2025 Nov 13:35:102547. [Abstract]
- Adv Healthc Mater. 2025 Sep;14(25):e2500507. [Abstract]
- Adv Healthc Mater. 2025 Jul 9:e2500592. [Abstract]
- Adv Healthc Mater. 2025 Jun;14(16):e2500546. [Abstract]
- J Hazard Mater. 2021 Sep 5:417:126092. [Abstract]
- Acta Biomater. 2024 Feb:175:250-261. [Abstract]
- Sci China Life Sci. 2022 Feb;65(2):341-361. [Abstract]
- Int J Nanomedicine. 2025 Dec 6:20:14613-14628. [Abstract]
- Int J Biol Macromol. 2025 Apr 28;310(Pt 4):143599. [Abstract]
- Drug Deliv. 2021 Dec;28(1):800-813. [Abstract]
- Int J Pharm X. 2026 May 3:11:100556. [Abstract]
- Clin Transl Med. 2025 Jan;15(1):e70191. [Abstract]
- ACS Appl Mater Interfaces. 2026 Apr 22;18(15):21500-21513. [Abstract]
- ACS Appl Mater Interfaces. 2020 Oct 14;12(41):45763-45771. [Abstract]
- Cell Rep. 2025 Dec 24;45(1):116797.
- Sci China Mater. 63, 620-628 (2020).
- Cancer Drug Resist. 2025 Aug 27:8:45. [Abstract]
- Genes Dev. 2021 Oct 1;35(19-20):1327-1332. [Abstract]
- J Med Chem. 2026 Apr 9;69(7):8417-8432. [Abstract]
- Environ Health. 2026 Apr 20.
- Anal Chem. 2020 Jan 21;92(2):2103-2111. [Abstract]
- Environ Pollut. 2026 Feb 1:390:127492. [Abstract]
- Emerg Microbes Infect. 2022 Dec;11(1):1135-1144. [Abstract]
- Pharmaceutics. 2024 Nov 21;16(12):1496. [Abstract]
- Pharmaceutics. 2020 Feb 17;12(2):167. [Abstract]
- J Cell Biol. 2025 May 5;224(5):e202405060. [Abstract]
- Biomacromolecules. 2021 Sep 13;22(9):3679-3691. [Abstract]
- Int Immunopharmacol. 2025 Jul 28:160:114918. [Abstract]
- Int J Mol Sci. 2025 Mar 29;26(7):3172. [Abstract]
- BMC Plant Biol. 2025 Feb 7;25(1):159. [Abstract]
- mBio. 2026 Apr 8;17(4):e0389625. [Abstract]
- J Pathol. 2023 May;260(1):17-31. [Abstract]
- ACS Appl Polym Mater. 2026 Feb 25.
- Eur J Pharm Sci. 2025 Sep 1:212:107188. [Abstract]
- Bioorg Chem. 2022 Apr:121:105651. [Abstract]
- PLoS Pathog. 2024 Nov 21;20(11):e1012681. [Abstract]
- Mol Pharm. 2021 Oct 4;18(10):3750-3762. [Abstract]
- Comput Struct Biotechnol J. 2021:19:1933-1943. [Abstract]
- iScience. 2023 Apr 7;26(5):106598. [Abstract]
- Aquaculture. 2026 May 4;623:744110.
- J Virol. 2025 Aug 25:e0022125. [Abstract]
- J Biol Chem. 2022 Nov;298(11):102511. [Abstract]
- J Virol. 2021 Nov 23;95(24):e0134521. [Abstract]
- Microb Pathog. 2025 Sep:206:107751. [Abstract]
- Carcinogenesis. 2024 Dec 30;45(12):953-964. [Abstract]
- Vet Res. 2023 Mar 14;54(1):24. [Abstract]
- Viruses. 2021 May 31;13(6):1035. [Abstract]
- Biotechnol J. 2023 Feb;18(2):e2200393. [Abstract]
- Nanotoxicology. 2022 Nov-Dec;16(9-10):895-912. [Abstract]
- Biochim Biophys Acta Gen Subj. 2023 Mar;1867(3):130300. [Abstract]
- Microvasc Res. 2021 Nov:138:104219. [Abstract]
- Exp Hematol. 2024 Dec:140:104651. [Abstract]
- Biol Open. 2023 Nov 15;12(11):bio060081. [Abstract]
- Icahn School of Medicine at Mount Sinai. 2026.
- bioRxiv. 2026 Mar 12.
- Cell Biomater. 2026 Mar 19.
- bioRxiv. 2026 Jan 17:2026.01.16.699967. [Abstract]
- bioRxiv. 2025 Nov 20.
- SSRN. 2025 Sep 30.
- Polym Sci Technol. 2025 Sep 15.
- bioRxiv. 2025 May 3:2025.04.29.651251. [Abstract]
- bioRxiv. 2024 Jan 10:2024.01.07.574541. [Abstract]
Customer Validation & Images
-
WB
-
RT-PCR
-
WB
-
Cell Imaging/Staining
-
Cell Imaging/Staining
Actividad biológica
|
COX-2 |
EIPA (100 μM, 30 min) suppresses TRPP3-mediated Ca2+ uptake in X. laevis oocytes[1].
EIPA hydrochloride (10-100 μM) reversibly inhibits the basal Na+ current (IC50: 19.5 μM)[1].
EIPA (300 μM, 6h) enhances autophagy through NHE3 (Na+/H+-exchanger 3) in IEC-18 cells[2].
EIPA (20 μM, 2 h) blocks macropinocytosis-mediated uptake of CA-PZ massively entry in HT-29 cells and MIA PaCa-2 cells[3].
EIPA (30 μM, 3h) attenuates Zinc/Kainate toxicity by decreasing Zn2+ entry in cerebellar granule neurons[4].
EIPA (5-100 μM, 48h) suppresses proliferation of MKN28 cells through up-regulation of p21 expression[5].
EIPA (3 μM, 6 h) inhibits the LPS-induced increase in the level of COX-2 protein[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MKN28 cells
-
Concentration:5, 10, 25, 50, and 100 μM
-
Incubation Time:48 h
-
Result:Inhibited cell proliferation in a dose- and time-dependent manner.
-
Cell Line:IEC-18 cells
-
Concentration:300 μM
-
Incubation Time:6 h
-
Result:Increased total LC3-II protein levels and P62 flux.
Increased ATG5, 7, 12 and P62 expression.
EIPA (oral administration, 10 mg/kg) inhibits LPS-induced inflammation in air pouch-type LPS-induced inflammation model[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male ddY strain mice[6]
-
Dosage:1 mg/kg
-
Administration:Intravenous injection
-
Result:Attenuated histologic renal damage, and imprved the I/R-induced increases in renal ET-1 contents.
-
Animal Model:Air pouch-type LPS-induced inflammation model[7]
-
Dosage:10 mg/kg
-
Administration:Oral administration
-
Result:Inhibited the LPS-induced infiltration of leukocytes into the pouch.
Inhibited the amount of PGE2 in the pouch fluid.
Chemical Information
-
No. CAS 1154-25-2
-
Appearance Solid
-
Peso molecular 299.76
-
Fòrmula C11H18ClN7O
-
Color White to yellow
-
SMILES
O=C(C1=NC(Cl)=C(N(CC)C(C)C)N=C1N)NC(N)=N
-
Synonyms
L593754; MH 12-43; Ethylisopropylamiloride
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 2 years -20°C 1 year
Publications (108)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Condensate nanovaccine adjuvants augment CD8+ T-Cell-dependent antitumor immunity through mtDNA leakage-triggered cGAS-STING axis activation. [Abstract]2025 Oct 21;10(1):349. PMID: 41115902 -
Cancer Cell
Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer. [Abstract]2025 Jul 15:S1535-6108(25)00271-5. PMID: 40712568
EIPA purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Jul 15:S1535-6108(25)00271-5. [Abstract]
Murine CAFs were cultured in 4 mM or 0.2 mM Q with DMSO or 25 μM EIPA hydrochloride for 4 h. The protein levels of sestrin2 (SESN2) were analyzed by western blot.
EIPA purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Jul 15:S1535-6108(25)00271-5. [Abstract]
Murine CAFs were cultured in 4 mM or 0.2 mM Q with DMSO or 25 μM EIPA for 32 h.
-
Mol Cancer
Tumour-infiltrating microplastics disrupt the JAK-STAT-microbiota axis to promote immunotherapy resistance in colorectal cancer. [Abstract]2026 Feb 10;25(1):73. PMID: 41664174 -
Nat Nanotechnol
2025 Feb;20(2):296-302. PMID: 39468359
EIPA purchased from MedChemExpress. Usage Cited in: Nat Nanotechnol. 2025 Feb;20(2):296-302. [Abstract]
EIPA (5 μg/mL, 24 h) could not reverse 500 nM NTZ-NPs induced EGFR protein degradation in MDA-MB-231 cells.
-
Cell Metab
Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol production. [Abstract]2022 Dec 6;34(12):2018-2035.e8. PMID: 36351432
EIPA purchased from MedChemExpress. Usage Cited in: Cell Metab. 2022 Dec 6;34(12):2018-2035.e8. [Abstract]
Bone marrow cells cultured in medium containing 10 ng/mL GM-CSF for 3 days were treated with 2 μg PKH67-labeled sEVs with or without Amiloride (10 μM), Chlorpromazine (10 μM), or EIPA (5 μM) for 1 h. The median fluorescence intensity (MFI) of PKH67 was assessed by flow cytometry.
-
Adv Mater
Self-Sustained Biophotocatalytic Nano-Organelle Reactors with Programmable DNA Switches for Combating Tumor Metastasis. [Abstract]2025 Mar;37(9):e2415030. PMID: 39797479
EIPA purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Mar;37(9):e2415030. [Abstract]
EIPA (50 μM, 7 h) decreased the internalization efficiency of F/G/H-GNC in 4T1 cells by approximately 17%.
-
Bioact Mater
Three-dimensional printed PCL/nHA scaffolds promote soft tissue functional fibrosis to repair chest wall defect via Piezo1/Ca2+ signal during respiratory motion. [Abstract]2026 Apr 3:62:846-861. PMID: 42004622 -
Cancer Res
Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer. [Abstract]2025 Oct 9. PMID: 41066596
EIPA purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Oct 9. [Abstract]
EIPA (30 μM, 24 h) could not completely block the signal enhancement of FITC-EV mediated by P-3 Fax-Neu5Ac in RT-112 and KU-19-19 cells.
-
Cancer Res
Antigen Cross-Presentation by Type-2 Innate Lymphoid Cells Facilitates the Activation of Antitumor CD8+ T Cells. [Abstract]2025 Apr 17. PMID: 40245114 -
Bone Res
Pak4-mediated crosstalk between necroptotic macrophages and tendon stem/progenitor cells contributes to traumatic heterotopic ossification formation. [Abstract]2025 Oct 20;13(1):88. PMID: 41111094 -
EIPA purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 2021 Apr 1.
EIPA (100 μM, 5 h) inhibited the intracellular uptake of antigenic peptides GT83-Mn2+/OVA257-280-FITC NPs in DC2.4 cells.
-
Autophagy
SDC1-dependent TGM2 determines radiosensitivity in glioblastoma by coordinating EPG5-mediated fusion of autophagosomes with lysosomes. [Abstract]2023 Mar;19(3):839-857. PMID: 35913916 -
Nat Commun
Ocular delivery of lipid nanoparticles-formulated mRNA encoding lanosterol synthase ameliorates cataract in rats. [Abstract]2025 Sep 26;16(1):8522. PMID: 41006301 -
Nat Commun
Harnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors via the TRAIN mechanism. [Abstract]2025 Feb 4;16(1):1327. PMID: 39900573 -
Nat Commun
Tubeimosides are pan-coronavirus and filovirus inhibitors that can block their fusion protein binding to Niemann-Pick C1. [Abstract]2024 Jan 2;15(1):162. PMID: 38167417 -
ACS Nano
2026 Jun 30;20(25):18533-18544. PMID: 42304955 -
ACS Nano
Synergizing Ferroptosis Suppressor Protein 1 Gene Silencing and Photodynamic Therapy Based on Photosensitive Lipid Nanoparticles for Colon Cancer Immunotherapy. [Abstract]2025 Aug 19;19(32):29341-29359. PMID: 40772591 -
ACS Nano
Ototoxicity-Alleviating and Cytoprotective Allomelanin Nanomedicine for Efficient Sensorineural Hearing Loss Treatment. [Abstract]2024 Sep 11. PMID: 39259947 -
ACS Nano
Modular Peptide Probe for Pre/Intra/Postoperative Therapeutic to Reduce Recurrence in Ovarian Cancer. [Abstract]2020 Nov 24;14(11):14698-14714. PMID: 33174739 -
-
J Nanobiotechnology
GRP75-driven, cell-cycle-dependent macropinocytosis of Tat/pDNA-Ca2+ nanoparticles underlies distinct gene therapy effect in ovarian cancer. [Abstract]2022 Jul 20;20(1):340. PMID: 35858873 -
J Nanobiotechnology
An enhanced antioxidant strategy of astaxanthin encapsulated in ROS-responsive nanoparticles for combating cisplatin-induced ototoxicity. [Abstract]2022 Jun 10;20(1):268. PMID: 35689218 -
Theranostics
Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer. [Abstract]2022 Jan 1;12(3):1061-1073. PMID: 35154474 -
-
Adv Sci (Weinh)
Piezo1 Channel Mediates Mechanically Programmable Drug Delivery to Potentiate Intravesical Chemotherapy. [Abstract]2026 Mar 4:e22936. PMID: 41782384 -
Adv Sci (Weinh)
Physiological pH Transition-Driven Protein Corona Dynamics Regulate Cellular Uptake and Inflammatory Responses of Silica Nanoparticles. [Abstract]2025 Sep 3:e02788. PMID: 40902197 -
Adv Sci (Weinh)
IR783-Stabilized Nanodrugs Enhance Anticancer Immune Response by Synergizing Oxidation Therapy and Epigenetic Modulation. [Abstract]2025 Jun;12(21):e2415684. PMID: 40150864 -
Adv Sci (Weinh)
Bone-Targeted Fluoropeptide Nanoparticle Inhibits NF-κB Signaling to Treat Osteosarcoma and Tumor-Induced Bone Destruction. [Abstract]2025 Jan;12(1):e2412014. PMID: 39501934 -
Sci Adv
2020 Aug 12;6(33):eaaz1774. PMID: 32851155 -
Biomaterials
Engineered bacteriophage nanoassemblies in vivo stabilize DC-T cell immune synapse for high-performance influenza vaccination. [Abstract]2026 Aug:331:124113. PMID: 41795404 -
Biomaterials
Oral delivery of decanoic acid conjugated plant protein shell incorporating hybrid nanosystem leverage intestinal absorption of polyphenols. [Abstract]2022 Feb:281:121373. PMID: 35063742 -
Carbohydr Polym
Premna microphylla Turcz pectin-modified diosmetin nanoparticles: A galectin-3 targeting strategy for precise colitis intervention. [Abstract]2025 Nov 15;368(Pt 1):124067. PMID: 40912828 -
-
J Control Release
2026 Mar 10:391:114591. PMID: 41478376 -
J Control Release
Intravitreal delivery of LATS1 mRNA by lipid nanoparticles as an effective strategy for uveal melanoma therapy. [Abstract]2026 May 10:393:114784. PMID: 41786044 -
J Control Release
Cyclization and thermal modulation of a β-hairpin peptide for efficient cellular delivery. [Abstract]2026 Feb 10:390:114551. PMID: 41412216 -
J Control Release
Enzyme-instructed disassembly of phosphorylated temporin supramolecules enhances doxorubicin synergy for targeted cancer inhibition. [Abstract]2025 Nov 10:387:114176. PMID: 40886776 -
J Control Release
Intravitreal injection of cell membrane-coated nanoparticles for retinoblastoma treatment. [Abstract]2025 Sep 10:385:113939. PMID: 40484284 -
J Control Release
A facile and smart strategy to enhance bone regeneration with efficient vitamin D3 delivery through sterosome technology. [Abstract]2024 Jun:370:140-151. PMID: 38653347 -
J Control Release
Dual-responsive bioconjugates bearing a bifunctional adaptor for robust cytosolic peptide delivery. [Abstract]2023 Mar:355:675-684. PMID: 36791993 -
J Control Release
2022 Nov:351:703-712. PMID: 36202150 -
Cell Death Dis
Pictilisib and nutrient stress synergize to induce methuosis via PI(4,5)P2-dependent macropinocytic dysregulation in cancer cells. [Abstract]2026 Jun 16. PMID: 42303628 -
Cell Death Dis
Perforin-2 enhances antigen-specific CTL immune response by promoting cross presentation. [Abstract]2026 Apr 9;17(1):485. PMID: 41951589 -
Cell Death Dis
Mitochondrial, metabolic and bioenergetic adaptations drive plasticity of colorectal cancer cells and shape their chemosensitivity. [Abstract]2025 Apr 5;16(1):253. PMID: 40185729 -
J Exp Med
Repurposing a tricyclic antidepressant in tumor and metabolism disease treatment through fatty acid uptake inhibition. [Abstract]2023 Mar 6;220(3):e20221316. PMID: 36520461 -
J Neuroinflammation
Monocytes release cystatin F dimer to associate with Aβ and aggravate amyloid pathology and cognitive deficits in Alzheimer's disease. [Abstract]2024 May 10;21(1):125. PMID: 38730470 -
Mater Today Bio
SLC7A11-independent disulfidptosis induced by a two-pronged delivery strategy for bladder cancer chemotherapy and cisplatin-resistance reverse. [Abstract]2025 Nov 13:35:102547. PMID: 41322137 -
Adv Healthc Mater
Lipoprotein-Based Nanocatalyst Enables Targeted Treatment of APAP-Induced Liver Injury via Enhanced Macropinocytosis. [Abstract]2025 Sep;14(25):e2500507. PMID: 40411876 -
Adv Healthc Mater
Glyco Ionic Liquids as Novel Nanoparticle Coatings to Enhance Triple-Negative Breast Cancer Drug Delivery. [Abstract]2025 Jul 9:e2500592. PMID: 40635271 -
Adv Healthc Mater
CLDN18.2 CAR-derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer. [Abstract]2025 Jun;14(16):e2500546. PMID: 40384272 -
J Hazard Mater
Systematic toxicity evaluation of polystyrene nanoplastics on mice and molecular mechanism investigation about their internalization into Caco-2 cells. [Abstract]2021 Sep 5:417:126092. PMID: 34015712 -
Acta Biomater
Suicide gene delivery by morphology-adaptable enantiomeric peptide assemblies for combined ovarian cancer therapy. [Abstract]2024 Feb:175:250-261. PMID: 38122884 -
Sci China Life Sci
2022 Feb;65(2):341-361. PMID: 34047913 -
Int J Nanomedicine
2025 Dec 6:20:14613-14628. PMID: 41383278 -
Int J Biol Macromol
2025 Apr 28;310(Pt 4):143599. PMID: 40306505 -
Drug Deliv
The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death. [Abstract]2021 Dec;28(1):800-813. PMID: 33866918 -
Int J Pharm X
A reduction-sensitive lipophilic dihydroartemisinin prodrug in a self-microemulsifying drug delivery system for treating breast cancer lung metastasis via intestinal lymphatic transport. [Abstract]2026 May 3:11:100556. PMID: 42110369 -
Clin Transl Med
Vitamin K-dependent gamma-carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosine kinase receptor EGFR. [Abstract]2025 Jan;15(1):e70191. PMID: 39843398 -
ACS Appl Mater Interfaces
2026 Apr 22;18(15):21500-21513. PMID: 41968920 -
ACS Appl Mater Interfaces
In Vivo Tracking of Fluorinated Polypeptide Gene Carriers by Positron Emission Tomography Imaging. [Abstract]2020 Oct 14;12(41):45763-45771. PMID: 32940028 -
-
-
Cancer Drug Resist
Cryptotanshinone differentially induces cell death in ATP6V0D1-deficient pancreatic cancer cells. [Abstract]2025 Aug 27:8:45. PMID: 41019981 -
Genes Dev
USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer. [Abstract]2021 Oct 1;35(19-20):1327-1332. PMID: 34531315 -
J Med Chem
Hsp70-Targeting Chimeras Enable Dual Proteasomal and Lysosomal Degradation of Intracellular and Extracellular Proteins. [Abstract]2026 Apr 9;69(7):8417-8432. PMID: 41874277 -
-
Anal Chem
Chemoenzymatic Labeling of Extracellular Vesicles for Visualizing Their Cellular Internalization in Real Time. [Abstract]2020 Jan 21;92(2):2103-2111. PMID: 31876137 -
Environ Pollut
Polystyrene nanoplastics promote fish iridovirus replication via inducing inflammatory response, antioxidant damage and enhancing viral entry. [Abstract]2026 Feb 1:390:127492. PMID: 41349949 -
Emerg Microbes Infect
SARS-CoV-2 pseudovirus enters the host cells through spike protein-CD147 in an Arf6-dependent manner. [Abstract]2022 Dec;11(1):1135-1144. PMID: 35343395
EIPA purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2022 Dec;11(1):1135-1144. [Abstract]
The blocking effect of EIPA hydrochloride (30 μM) on dextran, CPZ (25 μM) on transferrin, and MCD (3 mM) or filipin III (1 μg/ml) on CTB was observed in Vero E6 cells. Hoechst was used to stain the nuclei.
-
Pharmaceutics
Enhanced Ocular Bioavailability and Prolonged Duration via Hydrophilic Surface Nanocomposite Vesicles for Topical Drug Administration. [Abstract]2024 Nov 21;16(12):1496. PMID: 39771476 -
Pharmaceutics
Transport Mechanisms of Polymannuronic Acid and Polyguluronic Acid Across Caco-2 Cell Monolayers. [Abstract]2020 Feb 17;12(2):167. PMID: 32079270 -
J Cell Biol
2025 May 5;224(5):e202405060. PMID: 40136051
EIPA purchased from MedChemExpress. Usage Cited in: J Cell Biol. 2025 May 5;224(5):e202405060. [Abstract]
Agarose gel of Xbp1 cDNA amplicons in AML12 treated with Ctrl/CM ± endocytosis inhibitors (amiloride, nocodazole, nystatin, EIPA hydrochloride (40 μM)).
-
Biomacromolecules
2021 Sep 13;22(9):3679-3691. PMID: 34383480 -
Int Immunopharmacol
Type I and II pili mediate Streptococcus pneumoniae invasion into human blood-brain barrier-derived cells through extracellular matrix protein receptors and different endocytosis pathways. [Abstract]2025 Jul 28:160:114918. PMID: 40449266 -
Int J Mol Sci
D-M159 Synergistically Induces Apoptosis in HeLa Cells Through Endoplasmic Reticulum Stress and Mitochondrial Dysfunction. [Abstract]2025 Mar 29;26(7):3172. PMID: 40243937 -
BMC Plant Biol
Investigating the role of endocytosis in the uptake of photoassimilates in Gracilariopsis lemaneiformis (Rhodophyta). [Abstract]2025 Feb 7;25(1):159. PMID: 39915741 -
mBio
ATP1A1 enhances porcine reproductive and respiratory syndrome virus type 2 attachment and internalization. [Abstract]2026 Apr 8;17(4):e0389625. PMID: 41773865 -
J Pathol
The phospholipid flippase ATP9A enhances macropinocytosis to promote nutrient starvation tolerance in hepatocellular carcinoma. [Abstract]2023 May;260(1):17-31. PMID: 36715683 -
-
Eur J Pharm Sci
Chemical coupling of an active/passive dual-targeting fusion protein ER(Fv)-HSA to DM1 improves its tumor-specificity and therapeutic efficacy against pancreatic cancer. [Abstract]2025 Sep 1:212:107188. PMID: 40609662 -
Bioorg Chem
Discovery of a Nur77-mediated cytoplasmic vacuolation and paraptosis inducer (4-PQBH) for the treatment of hepatocellular carcinoma. [Abstract]2022 Apr:121:105651. PMID: 35182885 -
PLoS Pathog
Massive entry of BK Polyomavirus induces transient cytoplasmic vacuolization of human renal proximal tubule epithelial cells. [Abstract]2024 Nov 21;20(11):e1012681. PMID: 39570904 -
Mol Pharm
2021 Oct 4;18(10):3750-3762. PMID: 34491767
EIPA purchased from MedChemExpress. Usage Cited in: Mol Pharm. 2021 Oct 4;18(10):3750-3762. [Abstract]
The cellular fluorescence profiles showed 5-TAMRA-RRL signals were sharply inhibited by Pitstop 2, EIPA hydrochloride (100 μM) and VER-155008 (20 μM).
-
Comput Struct Biotechnol J
Dependence of SARS-CoV-2 infection on cholesterol-rich lipid raft and endosomal acidification. [Abstract]2021:19:1933-1943. PMID: 33850607 -
iScience
Amphibian pore-forming protein βγ-CAT drives extracellular nutrient scavenging under cell nutrient deficiency. [Abstract]2023 Apr 7;26(5):106598. PMID: 37128610 -
-
J Virol
SFTSV utilizes AXL/GAS6 for entry via PI3K-PLC-dependent macropinocytosis activated by AXL-kinase. [Abstract]2025 Aug 25:e0022125. PMID: 40853130 -
J Biol Chem
SARS-CoV-2 hijacks macropinocytosis to facilitate its entry and promote viral spike-mediated cell-to-cell fusion. [Abstract]2022 Nov;298(11):102511. PMID: 36259516 -
J Virol
Porcine Deltacoronavirus Enters Porcine IPI-2I Intestinal Epithelial Cells via Macropinocytosis and Clathrin-Mediated Endocytosis Dependent on pH and Dynamin. [Abstract]2021 Nov 23;95(24):e0134521. PMID: 34586858 -
Microb Pathog
EIPA, A macropinocytosis blocking agent, inhibits Siniperca chuatsi rhabdovirus infection in vitro and in vivo. [Abstract]2025 Sep:206:107751. PMID: 40436219 -
Carcinogenesis
Macropinocytosis inhibits alkaliptosis in pancreatic cancer cells through fatty acid uptake. [Abstract]2024 Dec 30;45(12):953-964. PMID: 39008332 -
Vet Res
Fowl adenovirus serotype 4 enters leghorn male hepatocellular cells via the clathrin-mediated endocytosis pathway. [Abstract]2023 Mar 14;54(1):24. PMID: 36918926 -
Viruses
Bovine Parainfluenza Virus Type 3 (BPIV3) Enters HeLa Cells via Clathrin-Mediated Endocytosis in a Cholesterol- and Dynamin-Dependent Manner. [Abstract]2021 May 31;13(6):1035. PMID: 34072688 -
Biotechnol J
Yeast-derived vacuoles as a novel carrier with enhanced hCMEC/D3 cell monolayer penetration. [Abstract]2023 Feb;18(2):e2200393. PMID: 36321515 -
Nanotoxicology
Evaluation of cytotoxicity and biodistribution of mesoporous carbon nanotubes (pristine/-OH/-COOH) to HepG2 cells in vitro and healthy mice in vivo. [Abstract]2022 Nov-Dec;16(9-10):895-912. PMID: 36704847 -
Biochim Biophys Acta Gen Subj
An integrative method for evaluating the biological effects of nanoparticle-protein corona. [Abstract]2023 Mar;1867(3):130300. PMID: 36577488 -
Microvasc Res
Dynamin-2 mediates clathrin-dependent endocytosis for amyloid-β internalization in brain microvascular endothelial cells. [Abstract]2021 Nov:138:104219. PMID: 34214572 -
Exp Hematol
Cellular uptake of CPX-351 by scavenger receptor class B type 1-mediated nonendocytic pathway. [Abstract]2024 Dec:140:104651. PMID: 39362576 -
Biol Open
The autotaxin-LPA axis promotes membrane trafficking and secretion in yolk sac visceral endoderm cells. [Abstract]2023 Nov 15;12(11):bio060081. PMID: 37795611 -
-
-
-
bioRxiv
Distinct sensing of BCAAs by mTOR and c-Myc governs T cell proliferation, independent of catabolism. [Abstract]2026 Jan 17:2026.01.16.699967. PMID: 41648372 -
-
-
-
bioRxiv
NF2 loss malignantly transforms human pancreatic acinar cells and enhances cell fitness under environmental stress. [Abstract]2025 May 3:2025.04.29.651251. PMID: 40655016 -
bioRxiv
2024 Jan 10:2024.01.07.574541. PMID: 38260395
Solvente y solubilidad
DMSO : 100 mg/mL (333.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (8.34 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (8.34 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Dai XQ, et al. Inhibition of TRPP3 channel by MK-870 and analogs. Mol Pharmacol. 2007 Dec;72(6):1576-85. [Content Brief]
[2]. Shi H, et al. Na+/H+ Exchanger Regulates Amino Acid-Mediated Autophagy in Intestinal Epithelial Cells. Cell Physiol Biochem. 2017;42(6):2418-2429. [Content Brief]
[3]. Zhu BY, et al. A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis. [Content Brief]
[4]. E V Stelmashook, et al. Acidosis and 5-(N-ethyl-N-isopropyl)amiloride (EIPA) Attenuate Zinc/Kainate Toxicity in Cultured Cerebellar Granule Neurons. Biochemistry (Mosc). 2015 Aug;80(8):1065-72. [Content Brief]
[5]. Shigekuni Hosogi, et al. An inhibitor of Na(+)/H(+) exchanger (NHE), ethyl-isopropyl amiloride (EIPA), diminishes proliferation of MKN28 human gastric cancer cells by decreasing the cytosolic Cl(-) concentration via DIDS-sensitive pathways. Cell Physiol Biochem. 2012;30(5):1241-53. [Content Brief]
[6]. Junji Yamashita, et al. Role of Na+/H+ exchanger in the pathogenesis of ischemic acute renal failure in mice. J Cardiovasc Pharmacol. 2007 Mar;49(3):154-60. [Content Brief]
[7]. Fumitaka Kamachi, et al. Inhibition of lipopolysaccharide-induced prostaglandin E2 production and inflammation by the Na+/H+ exchanger inhibitors. J Pharmacol Exp Ther. 2007 Apr;321(1):345-52. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3360 mL | 16.6800 mL | 33.3600 mL | 83.4001 mL |
| 5 mM | 0.6672 mL | 3.3360 mL | 6.6720 mL | 16.6800 mL | |
| 10 mM | 0.3336 mL | 1.6680 mL | 3.3360 mL | 8.3400 mL | |
| 15 mM | 0.2224 mL | 1.1120 mL | 2.2240 mL | 5.5600 mL | |
| 20 mM | 0.1668 mL | 0.8340 mL | 1.6680 mL | 4.1700 mL | |
| 25 mM | 0.1334 mL | 0.6672 mL | 1.3344 mL | 3.3360 mL | |
| 30 mM | 0.1112 mL | 0.5560 mL | 1.1120 mL | 2.7800 mL | |
| 40 mM | 0.0834 mL | 0.4170 mL | 0.8340 mL | 2.0850 mL | |
| 50 mM | 0.0667 mL | 0.3336 mL | 0.6672 mL | 1.6680 mL | |
| 60 mM | 0.0556 mL | 0.2780 mL | 0.5560 mL | 1.3900 mL | |
| 80 mM | 0.0417 mL | 0.2085 mL | 0.4170 mL | 1.0425 mL | |
| 100 mM | 0.0334 mL | 0.1668 mL | 0.3336 mL | 0.8340 mL |
EIPA Related Classifications
HY-101840 Related Classifications
Powered by Bioz